4.7 Review

Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma

Journal

Publisher

MDPI
DOI: 10.3390/ijms19113621

Keywords

multiple myeloma; prevention; monoclonal gammopathy of undetermined significance; plasma cell disease; therapy

Funding

  1. American Cancer Society [IRG-15-176-40]
  2. NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Multiple myeloma is an invariably fatal cancer of plasma cells. Despite tremendous advances in treatment, this malignancy remains incurable in most individuals. We postulate that strategies aimed at prevention have the potential to be more effective in preventing myeloma-related death than additional pharmaceutical strategies aimed at treating advanced disease. Here, we present a rationale for the development of prevention therapy and highlight potential target areas of study.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available